Studies on the role of calcium in the 5-HT-stimulated release of glutamate from C6 glioma cells

被引:3
|
作者
Meller, R
Harrison, PJ
Sharp, T
机构
[1] Univ Oxford, Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England
[2] Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England
关键词
5-hydroxytryptamine; glial calcium; IP3; glutamate;
D O I
10.1016/S0014-2999(02)01718-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We recently reported that 5-hydroxytryptamine(2A) (5-HT2A) receptor activation on cultured glial cells induces glutamate release [J. Neurosci. Res. 67 (2002) 399]. Here we use C6 glioma cells to examine the role of calcium in this response. 5-Hydroxytryptamine (5-HT) increases glutamate release from C6 glioma cells, an effect blocked by low calcium conditions. The calcium ionophores ionomycin and calcimycin also released glutamate from C6 glioma cells in a Ca2+-dependent manner, The effect of 5-HT was reduced by the phospholipase C inhibitor U73122 (1-[6[[(17beta)-3-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione), but not its inactive enantomer U73343 (1-[6 [[(17beta)-3-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-2,5-pyrrolidinedione). The protein kinase C inhibitors staurosporine and calphostin C had no effect on the response to 5-HT, whereas the response was blocked by thapsigargin and caffeine. Neither the L-type calcium channel blockers, nifedipine and verapamil, nor the N-type calcium channel blocker omega-conotoxin GVlA inhibited the effect of 5-HT, whereas NiCl2 and KCl blocked the response to 5-HT. We conclude that the 5-HT-induced efflux of glutamate from C6 glioma cells is Ca2+ dependent and involves, at least in part, the mobilisation of Ca2+ from mositol (1,4,5) tris phosphate (IP3) sensitive intracellular stores. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:13 / 19
页数:7
相关论文
共 50 条
  • [21] Evidence for purine nucleoside phosphorylase (PNP) release from rat C6 glioma cells
    Giuliani, Patricia
    Zuccarini, Mariachiara
    Buccella, Silvana
    Pena-Altamira, Luis Emiliano
    Polazzi, Elisabetta
    Virgili, Marco
    Monti, Barbara
    Poli, Alessandro
    Rathbone, Michel P.
    Di Iorio, Patrizia
    Ciccarelli, Renata
    Caciagli, Francesco
    JOURNAL OF NEUROCHEMISTRY, 2017, 141 (02) : 208 - 221
  • [22] Effect of mtDNA depletion from C6 glioma cells and characteristics of the generated C6ρ0 cells
    Jin, Youcai
    Luan, Guangxiang
    Li, Ji
    Wang, Honglun
    Wang, Zhenhua
    Bai, Bo
    MOLECULAR MEDICINE REPORTS, 2021, 23 (04)
  • [23] Does flatter means faster? Studies on local dynamics of calcium transients in glioma C6 cells
    Wypych, D.
    Pomorski, P.
    FEBS JOURNAL, 2009, 276 : 257 - 257
  • [24] Role of G(q alpha) in insulin-stimulated glucose uptake by C6 glioma cells.
    Singh, SP
    Gao, Y
    Kunapuli, SP
    Ravindra, RJ
    DIABETES, 1997, 46 : 1354 - 1354
  • [25] Resveratrol increases glutamate uptake and glutamine synthetase activity in C6 glioma cells
    dos Santos, Andre Quincozes
    Nardin, Patricia
    Funchal, Claudia
    Vielra de Almeida, Lucia Maria
    Jacques-Silva, Maria Caroline
    Wofchuk, Susana T.
    Goncalves, Carlos-Alberto
    Gottfried, Carmem
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2006, 453 (02) : 161 - 167
  • [26] Calcium-mediated endothelin signaling in C6 rat glioma cells
    Sedo, A
    Malík, R
    Vlasicová, K
    Rovero, P
    NEUROPEPTIDES, 1999, 33 (01) : 13 - 17
  • [27] Calcium-mediated endothelin signaling in C6 rat glioma cells
    Malik, R
    Rovero, P
    Vlasicova, K
    Sedo, A
    FASEB JOURNAL, 1997, 11 (09): : A1163 - A1163
  • [28] Capacitative calcium entry. Glioma C6 as a model of nonexcitable cells
    Baranska, J
    Przybylek, K
    Sabala, P
    POLISH JOURNAL OF PHARMACOLOGY, 1999, 51 (02): : 153 - 162
  • [29] Role of GPR30 in proliferation of C6 glioma cells
    Kanda, Yasunari
    Nakazawa, Ken
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2009, 109 : 276P - 276P
  • [30] 5-HT2A receptor activation leads to increased BDNF mRNA expression in C6 glioma cells
    Meller, R
    Babity, JM
    Grahame-Smith, DG
    NEUROMOLECULAR MEDICINE, 2002, 1 (03) : 197 - 205